Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Emerg Infect Dis ; 25(5): 1023-1025, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30753125

RESUMEN

We note the reemergence of human monkeypox in Sierra Leone following a 44-year absence of reported disease. The persons affected were an 11-month-old boy and, several years later, a 35-year-old man. The reappearance of monkeypox in this country suggests a need for renewed vigilance and awareness of the disease and its manifestations.


Asunto(s)
Enfermedades Transmisibles Emergentes/diagnóstico , Enfermedades Transmisibles Emergentes/epidemiología , Mpox/diagnóstico , Mpox/epidemiología , Adulto , Enfermedades Transmisibles Emergentes/virología , Notificación de Enfermedades , Humanos , Lactante , Masculino , Mpox/virología , Vigilancia en Salud Pública , Vigilancia de Guardia , Sierra Leona/epidemiología
2.
J Infect Dis ; 214(suppl 3): S210-S217, 2016 10 15.
Artículo en Inglés | MEDLINE | ID: mdl-27587634

RESUMEN

BACKGROUND: Ebola virus disease (EVD) is a severe viral illness caused by Ebola virus (EBOV). The 2013-2016 EVD outbreak in West Africa is the largest recorded, with >11 000 deaths. Development of the ReEBOV Antigen Rapid Test (ReEBOV RDT) was expedited to provide a point-of-care test for suspected EVD cases. METHODS: Recombinant EBOV viral protein 40 antigen was used to derive polyclonal antibodies for RDT and enzyme-linked immunosorbent assay development. ReEBOV RDT limits of detection (LOD), specificity, and interference were analytically validated on the basis of Food and Drug Administration (FDA) guidance. RESULTS: The ReEBOV RDT specificity estimate was 95% for donor serum panels and 97% for donor whole-blood specimens. The RDT demonstrated sensitivity to 3 species of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus) associated with human disease, with no cross-reactivity by pathogens associated with non-EBOV febrile illness, including malaria parasites. Interference testing exhibited no reactivity by medications in common use. The LOD for antigen was 4.7 ng/test in serum and 9.4 ng/test in whole blood. Quantitative reverse transcription-polymerase chain reaction testing of nonhuman primate samples determined the range to be equivalent to 3.0 × 105-9.0 × 108 genomes/mL. CONCLUSIONS: The analytical validation presented here contributed to the ReEBOV RDT being the first antigen-based assay to receive FDA and World Health Organization emergency use authorization for this EVD outbreak, in February 2015.


Asunto(s)
Antígenos Virales/sangre , Brotes de Enfermedades , Ebolavirus/inmunología , Fiebre Hemorrágica Ebola/diagnóstico , Sistemas de Atención de Punto , Proteínas de la Matriz Viral/sangre , África Occidental/epidemiología , Animales , Ebolavirus/aislamiento & purificación , Ensayo de Inmunoadsorción Enzimática , Fiebre Hemorrágica Ebola/virología , Humanos , Inmunoensayo , Límite de Detección , Juego de Reactivos para Diagnóstico , Sensibilidad y Especificidad
3.
J Virol ; 90(6): 2920-7, 2015 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-26719273

RESUMEN

UNLABELLED: Approximately one-third of Lassa virus (LASV)-infected patients develop sensorineural hearing loss (SNHL) in the late stages of acute disease or in early convalescence. With 500,000 annual cases of Lassa fever (LF), LASV is a major cause of hearing loss in regions of West Africa where LF is endemic. To date, no animal models exist that depict the human pathology of LF with associated hearing loss. Here, we aimed to develop an animal model to study LASV-induced hearing loss using human isolates from a 2012 Sierra Leone outbreak. We have recently established a murine model for LF that closely mimics many features of human disease. In this model, LASV isolated from a lethal human case was highly virulent, while the virus isolated from a nonlethal case elicited mostly mild disease with moderate mortality. More importantly, both viruses were able to induce SNHL in surviving animals. However, utilization of the nonlethal, human LASV isolate allowed us to consistently produce large numbers of survivors with hearing loss. Surviving mice developed permanent hearing loss associated with mild damage to the cochlear hair cells and, strikingly, significant degeneration of the spiral ganglion cells of the auditory nerve. Therefore, the pathological changes in the inner ear of the mice with SNHL supported the phenotypic loss of hearing and provided further insights into the mechanistic cause of LF-associated hearing loss. IMPORTANCE: Sensorineural hearing loss is a major complication for LF survivors. The development of a small-animal model of LASV infection that replicates hearing loss and the clinical and pathological features of LF will significantly increase knowledge of pathogenesis and vaccine studies. In addition, such a model will permit detailed characterization of the hearing loss mechanism and allow for the development of appropriate diagnostic approaches and medical care for LF patients with hearing impairment.


Asunto(s)
Modelos Animales de Enfermedad , Pérdida Auditiva Sensorineural/patología , Fiebre de Lassa/complicaciones , Animales , Nervio Coclear/patología , Brotes de Enfermedades , Oído Interno/patología , Pérdida Auditiva Sensorineural/epidemiología , Histocitoquímica , Humanos , Fiebre de Lassa/epidemiología , Virus Lassa/aislamiento & purificación , Ratones , Microscopía , Sierra Leona/epidemiología , Virulencia
4.
Clin Infect Dis ; 51(12): 1435-41, 2010 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-21058912

RESUMEN

Lassa fever is an acute viral hemorrhagic illness; the virus is endemic in West Africa and also of concern with regard to bioterrorism. Transmission of Lassa virus between humans may occur through direct contact with infected blood or bodily secretions. Oral administration of the antiviral drug ribavirin is often considered for postexposure prophylaxis, but no systematically collected data or uniform guidelines exist for this indication. Furthermore, the relatively low secondary attack rates for Lassa fever, the restriction of the area of endemicity to West Africa, and the infrequency of high-risk exposures make it unlikely that controlled prospective efficacy trials will ever be possible. Recommendations for postexposure use of ribavirin can therefore be made only on the basis of a thorough understanding and logical extrapolation of existing data. Here, we review the pertinent issues and propose guidelines based on extensive review of the literature, as well as our experience in this field. We recommend oral ribavirin postexposure prophylaxis for Lassa fever exclusively for definitive high-risk exposures. These guidelines may also serve for exposure to other hemorrhagic fever viruses susceptible to ribavirin.


Asunto(s)
Antivirales/administración & dosificación , Quimioprevención/métodos , Fiebre de Lassa/prevención & control , Guías de Práctica Clínica como Asunto , Ribavirina/administración & dosificación , Humanos , Fiebre de Lassa/tratamiento farmacológico
5.
Antiviral Res ; 78(1): 103-15, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18241935

RESUMEN

Unlike many viral hemorrhagic fevers (VHFs), Lassa fever (LF) is not a rare disease that emerges only as sporadic cases or in outbreak form. Although surveillance is inadequate to determine the true incidence, up to 300,000 infections and 5000 deaths from LF are estimated to occur yearly. The highest incidence is in the "Mano River Union (MRU) countries" of Sierra Leone, Liberia, and Guinea. Although civil unrest in this region over the past two decades has impeded capacity building and research, new-found peace in recent years presents new opportunities. In 2004, the Mano River Union Lassa Fever Network (MRU LFN) was established to assist MRU countries in the development of national and regional surveillance, diagnosis, treatment, control, and prevention of LF. Here, we review the present literature on treatment and pathogenesis of LF and outline priorities for future research in the field made possible by the improved research capacity of the MRU LFN.


Asunto(s)
Antivirales/uso terapéutico , Fiebre de Lassa/tratamiento farmacológico , Fiebre de Lassa/fisiopatología , Virus Lassa/patogenicidad , Ribavirina/uso terapéutico , Adolescente , Adulto , África Occidental/epidemiología , Preescolar , Femenino , Humanos , Incidencia , Recién Nacido , Fiebre de Lassa/epidemiología , Fiebre de Lassa/virología , Virus Lassa/efectos de los fármacos , Masculino , Embarazo , Investigación/tendencias
6.
Nat Med ; 23(10): 1146-1149, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28869611

RESUMEN

There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Neutralizantes/uso terapéutico , Anticuerpos Antivirales/uso terapéutico , Fiebre de Lassa/prevención & control , Animales , Reacciones Cruzadas , Ensayo de Inmunoadsorción Enzimática , Humanos , Evasión Inmune/genética , Inmunohistoquímica , Virus Lassa/genética , Macaca fascicularis , ARN Viral/sangre , Distribución Aleatoria , Tasa de Supervivencia , Carga Viral
7.
Antiviral Res ; 133: 218-222, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27531367

RESUMEN

Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Anticuerpos Antivirales/farmacología , Fiebre de Lassa/virología , Virus Lassa/efectos de los fármacos , Animales , Anticuerpos Monoclonales/inmunología , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Cobayas , Humanos , Concentración 50 Inhibidora , Fiebre de Lassa/tratamiento farmacológico , Fiebre de Lassa/inmunología , Virus Lassa/inmunología , Pruebas de Neutralización
9.
PLoS Negl Trop Dis ; 9(1): e3398, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25569707

RESUMEN

BACKGROUND: Zoonotic infections, which transmit from animals to humans, form the majority of new human pathogens. Following zoonotic transmission, the pathogen may already have, or may acquire, the ability to transmit from human to human. With infections such as Lassa fever (LF), an often fatal, rodent-borne, hemorrhagic fever common in areas of West Africa, rodent-to-rodent, rodent-to-human, human-to-human and even human-to-rodent transmission patterns are possible. Indeed, large hospital-related outbreaks have been reported. Estimating the proportion of transmission due to human-to-human routes and related patterns (e.g. existence of super-spreaders), in these scenarios is challenging, but essential for planned interventions. METHODOLOGY/PRINCIPAL FINDINGS: Here, we make use of an innovative modeling approach to analyze data from published outbreaks and the number of LF hospitalized patients to Kenema Government Hospital in Sierra Leone to estimate the likely contribution of human-to-human transmission. The analyses show that almost [Formula: see text] of the cases at KGH are secondary cases arising from human-to-human transmission. However, we found much of this transmission is associated with a disproportionally large impact of a few individuals ('super-spreaders'), as we found only [Formula: see text] of human cases result in an effective reproduction number (i.e. the average number of secondary cases per infectious case) [Formula: see text], with a maximum value up to [Formula: see text]. CONCLUSIONS/SIGNIFICANCE: This work explains the discrepancy between the sizes of reported LF outbreaks and a clinical perception that human-to-human transmission is low. Future assessment of risks of LF and infection control guidelines should take into account the potentially large impact of super-spreaders in human-to-human transmission. Our work highlights several neglected topics in LF research, the occurrence and nature of super-spreading events and aspects of social behavior in transmission and detection.


Asunto(s)
Fiebre de Lassa/transmisión , Modelos Biológicos , Zoonosis , Animales , Infección Hospitalaria/transmisión , Humanos , Fiebre de Lassa/epidemiología , Sierra Leona/epidemiología
11.
Viral Immunol ; 28(1): 19-31, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25531344

RESUMEN

Lassa fever (LF) is a severe viral hemorrhagic fever caused by Lassa virus (LASV). The LF program at the Kenema Government Hospital (KGH) in Eastern Sierra Leone currently provides diagnostic services and clinical care for more than 500 suspected LF cases per year. Nearly two-thirds of suspected LF patients presenting to the LF Ward test negative for either LASV antigen or anti-LASV immunoglobulin M (IgM), and therefore are considered to have a non-Lassa febrile illness (NLFI). The NLFI patients in this study were generally severely ill, which accounts for their high case fatality rate of 36%. The current studies were aimed at determining possible causes of severe febrile illnesses in non-LF cases presenting to the KGH, including possible involvement of filoviruses. A seroprevalence survey employing commercial enzyme-linked immunosorbent assay tests revealed significant IgM and IgG reactivity against dengue virus, chikungunya virus, West Nile virus (WNV), Leptospira, and typhus. A polymerase chain reaction-based survey using sera from subjects with acute LF, evidence of prior LASV exposure, or NLFI revealed widespread infection with Plasmodium falciparum malaria in febrile patients. WNV RNA was detected in a subset of patients, and a 419 nt amplicon specific to filoviral L segment RNA was detected at low levels in a single patient. However, 22% of the patients presenting at the KGH between 2011 and 2014 who were included in this survey registered anti-Ebola virus (EBOV) IgG or IgM, suggesting prior exposure to this agent. The 2014 Ebola virus disease (EVD) outbreak is already the deadliest and most widely dispersed outbreak of its kind on record. Serological evidence reported here for possible human exposure to filoviruses in Sierra Leone prior to the current EVD outbreak supports genetic analysis that EBOV may have been present in West Africa for some time prior to the 2014 outbreak.


Asunto(s)
Brotes de Enfermedades , Fiebres Hemorrágicas Virales/epidemiología , Fiebres Hemorrágicas Virales/etiología , Anticuerpos Antibacterianos/sangre , Anticuerpos Antivirales/sangre , ADN Protozoario/sangre , Ensayo de Inmunoadsorción Enzimática , Fiebres Hemorrágicas Virales/patología , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Reacción en Cadena de la Polimerasa , ARN Viral/sangre , Estudios Retrospectivos , Estudios Seroepidemiológicos , Sierra Leona/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA